CFC1: A Protein Involved in Cell Adhesion and Tissue Organization

Target Name: CFC1

NCBI ID: G55997

CFC1

CFC1: A Protein Involved in Cell Adhesion and Tissue Organization

CFC1 (CFC1 鈥嬧?媣ariant 1) is a protein that is expressed in various tissues throughout the body, including the brain, heart, lungs, and liver. It is a member of the cryptic cadherin gene family, which is known for its role in cell- cell adhesion and tissue organization.

CFC1 is a 21-kDa protein that consists of 195 amino acid residues. It has a molecular weight of 21.9 kDa and a calculated pI of 6.5. CFC1 is predominantly expressed in the brain, where it is found in the tightly packed enol-modified In the nucleolus of the cell membrane. It is also expressed in other tissues, including heart, lungs, and liver.

CFC1 is involved in several physiological processes in the body, including cell adhesion, migration, and invasion. It is a critical regulator of the cell-cell adhesion process, as it helps to maintain the integrity of the intercellular junctions that form the tight junctions that define the boundaries between cells.

CFC1 is also involved in the regulation of cell migration and invasion. It has been shown to play a role in the migration of cancer cells through the bloodstream and has been identified as a potential drug target for several diseases, including cancer.

CFC1 has also been shown to be involved in the regulation of cell survival and proliferation. It has been shown to play a role in the regulation of cell survival by suppressing the pro-apoptotic protein Bax, which is involved in cell death.

CFC1 is also involved in the regulation of cell signaling pathways. It has been shown to play a role in the regulation of the PI3K/Akt signaling pathway, which is involved in the regulation of cellular signaling pathways that are important for cellular processes such as cell growth, differentiation, and survival.

CFC1 is a potential drug target for several diseases, including cancer. Several studies have shown that inhibiting CFC1 can lead to the inhibition of cellular processes that are important for the development and progression of cancer.

One of the most promising strategies for the development of CFC1 as a drug target is the use of small molecules. Many small molecules have been shown to inhibit the activity of CFC1, including inhibitors of the PI3K/Akt signaling pathway.

Another strategy for the development of CFC1 as a drug target is the use of monoclonal antibodies (monoclonal antibodies are laboratory-produced molecules that are derived from a single cell and contain a single gene). Monoclonal antibodies have been shown to be effective in targeting CFC1 and have been used to block its activity in several experiments.

CFC1 is also a potential biomarker for several diseases, including cancer. Its expression has been shown to be altered in a variety of diseases, including cancer, and it has been used as a biomarker for the diagnosis and prognosis of several diseases.

In conclusion, CFC1 is a protein that is involved in several physiological processes in the body, including cell adhesion, migration, and invasion. It is a critical regulator of the cell-cell adhesion process and is involved in the regulation of cell survival and proliferation. . Its expression is altered in a variety of diseases, including cancer, and it has been used as a potential drug target and biomarker. Further research is needed to fully understand the role of CFC1 in cellular processes and its potential as a drug target and biomarker. .

Protein Name: Cripto, FRL-1, Cryptic Family 1

Functions: NODAL coreceptor involved in the correct establishment of the left-right axis. May play a role in mesoderm and/or neural patterning during gastrulation

The "CFC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CFC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets